Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
D-Limonene (R-(+)-limonene) is a cyclic monoterpene found abundantly in citrus peel oil that exerts anticancer and anti-inflammatory effects primarily by modulating Ras protein prenylation, suppressing cyclin D1 expression, and activating apoptotic pathways. It concentrates preferentially in fatty tissues, including breast tissue, making it a candidate adjuvant in oncology research.
Origin & History
D-Limonene is a naturally occurring monoterpene hydrocarbon found primarily in citrus essential oils, with the highest concentrations in orange, lemon, and grapefruit peels. It is extracted through cold pressing or steam distillation of citrus rinds, yielding a cyclic monoterpene with the formula C10H16.
Research Narrative (Provisional)
Clinical evidence is limited to small phase I/II trials, including a phase I study (n=32, PMID: 9654110) establishing MTD at 8 g/m²/day with one partial response in breast cancer, and a phase II trial (n=43) showing breast tissue accumulation and cyclin D1 reduction. No randomized controlled trials or meta-analyses on D-limonene alone were identified.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
D-Limonene is a pure monocyclic monoterpene compound (C10H16, molecular weight 136.23 g/mol), not a nutritional food source, so conventional macronutrient/micronutrient framing does not apply. Bioactive compound content: essentially 100% R-(+)-limonene enantiomer when in purified form. Naturally occurs in citrus peel oils at concentrations of 40,000–960,000 mg/kg (40–96% of essential oil composition depending on species); orange peel oil contains approximately 680,000–960,000 mg/kg, lemon peel oil approximately 400,000–700,000 mg/kg. Caloric density as a lipophilic terpene is approximately 8.8 kcal/g (theoretical, as a hydrocarbon), but dietary exposure doses are typically 1–10 g/day in supplemental form, contributing negligible calories in practical use. Contains no protein, carbohydrates, fiber, vitamins, or minerals. Key bioactive properties stem from its monoterpene structure: highly lipophilic (log P ≈ 4.57), enabling strong tissue partitioning — confirmed breast tissue concentration of 41.3 μg/g at supplemental doses of ~2 g/day in human phase II data. Bioavailability: rapidly absorbed orally, undergoes hepatic metabolism to perillic acid, dihydroperillic acid, uroterpenol, and limonene-1,2-diol via CYP450 enzymes (primarily CYP2C19, CYP3A4); urinary metabolite perillic acid reaches plasma concentrations of approximately 30–50 μM at 2 g/day dosing. Half-life approximately 12–24 hours. No dietary fiber, no mineral content, no vitamin content.
Reported Mechanism (Provisional)
D-Limonene inhibits the post-translational prenylation of Ras and other small G-proteins by blocking farnesyl pyrophosphate transferase and geranylgeranyl transferase enzymes, disrupting downstream MAPK and PI3K/Akt proliferation signaling. It downregulates cyclin D1, a cell-cycle regulatory protein, thereby arresting tumor cells in G1 phase and reducing uncontrolled mitosis. Additionally, D-Limonene suppresses NF-κB activation and reduces pro-inflammatory cytokine production, including TNF-α and IL-6, contributing to its anti-inflammatory profile.
Clinical Narrative (Provisional)
A phase I dose-escalation trial in breast cancer patients demonstrated that oral D-Limonene produced one confirmed partial response lasting 11 months, establishing preliminary proof-of-concept for anticancer activity at tolerable doses. A subsequent phase II study (n=43) quantified tissue pharmacokinetics, confirming breast tissue concentrations of 41.3 μg/g and a statistically significant reduction in tumor cyclin D1 expression after supplementation. Evidence remains early-stage and limited to small trials without randomized placebo controls, so conclusions about efficacy must be considered preliminary. Anti-inflammatory effects have been documented in preclinical models but have not yet been confirmed in adequately powered human randomized controlled trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.